Novartis’ Migraine prevention therapy is closer to being approved

2018-06-04T13:44:50+00:0004/06/2018|Categories: Industry, News|Tags: , , , |

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes of years of disability worldwide. Aimovig is the first treatment of its kind specifically developed to prevent migraine, blocking the peptide related to the calcitonin gene (CGRPR), which plays an essential role in the pathology of migraine. If approved, Aimovig will be administered once a month [...]

First monoclonal antibody therapy for prevention of migraine

2018-06-01T16:43:40+00:0001/06/2018|Categories: Industry, News|Tags: , , , , |

First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks. It is estimated that approximately 15% of the European population suffers from migraine. Patients experience recurrent episodes of intense, throbbing headache, most often only on one side of the head. Sometimes, the [...]

Arnold Neuralgia/Recurrent occipital pain cause

2018-05-23T17:09:16+00:0023/05/2018|Categories: News|Tags: , , , , |

Recurrent, troublesome occipital pain associated with muscular tension is known as Arnold's neuralgia, a strange condition. The condition of peripheral nerves can produce the pain of varying intensity as a reflex mechanism, depending on the degree of damage being considered. Some anatomical locations are often associated with these syndromes, with the exception of the occipital region, in which it is rare to identify these elements. Occipital neuralgia is easy to diagnose and can be managed with pharmacological treatment, although there are some additional more invasive therapies in refractory cases. It's about their peculiarities what we'll talk about next. WHY IS [...]

A laboratory that takes care of its employees

2018-05-22T13:46:50+00:0022/05/2018|Categories: Industry, News|Tags: , , |

The following article shows a clear example of best practices at work and how important it is to have employees happy and satisfied at the workspace in order to have them working at their maximum possibilities. The pharmaceutical laboratory AbbVie recognizes that caring for the health and the well-being of its employees has an impact on a better professional performance and in this sense, on its fifth anniversary as an independent company, it has launched a program to improve the health of its employees and the balance between their personal and professional life. In this way, all its employees have a [...]

Galcanezumab-Cluster headache

2018-05-22T10:32:30+00:0022/05/2018|Categories: Industry, News|Tags: , |

Prevention of episodic cluster headache: Primary endpoint achieved in Phase 3 study 16/05/2018 Eli Lilly and Company announced that Galcanezumab met with the primary endpoint in a Phase 3 trial of episodic cluster headache patients, the statistically significant differences in reducing headache attacks In weekly clusters compared to placebo during the weeks one to three two-month double-blind treatment time shows. Weekly Cluster headache attacks A statistically significantly higher percentage of patients treated with galcanezumab also achieved a reduction in weekly cluster headache attacks by at least 50 percent compared to placebo in Week 3, the criterion of Secondary valuation. Security [...]

New Drug Offers Hope to Millions With Severe Migraines

2018-05-18T11:28:13+00:0018/05/2018|Categories: Industry, News|Tags: , |

The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a device similar to an insulin pen. The list price will be $6,900 a year, and Amgen said the drug will be available to patients within a week. Aimovig blocks a protein fragment, CGRP, that instigates and perpetuates migraines. Three other companies — Lilly, Teva and [...]

EPF publishes a guide for patient organisations on the new Data Protection Regulation

2018-05-07T19:06:17+00:0007/05/2018|Categories: Associations, News|Tags: |

The new Regulation on personal data protection (EU/2016/679) was published in May 2016 and will apply from May 2018. It provides more rights to citizens to be better informed about the use made of their personal data, and gives clearer responsibilities to people and entities using personal data. Patients’ fundamental right to protection of their health data is an important issue in diverse contexts such as healthcare, including care given through eHealth or in a cross-border healthcare context, and research (clinical trials, clinical investigations, epidemiological research, patient registries…). In this regard, EPF has drafted a guide for patients and patient organisations to explain what [...]

Migraines are associated with a polygenic inheritance

2018-05-07T18:41:25+00:0007/05/2018|Categories: News|Tags: |

A new study has found that some families are especially sensitive to migraines and that genetics influences the type of migraine suffered by affected people. Migraine is a disease that has as its main symptom headache, throbbing, unilateral, accompanied by nausea or vomiting, sensitivity to light or sounds, usually very intense and disabling for those who suffer it. It´s a very frequent condition, whose origin is a combination of genetic and environmental factors. It affects between 11% and 16% of the general population, with the highest incidence in women. It is more frequent in America, followed by Europe and finally [...]

Potential source of gender differences in migraines

2018-04-27T11:02:56+00:0027/04/2018|Categories: Industry, News|Tags: |

Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone estrogen affect cells in the brain. Of the more than 38 million Americans who experience migraine headaches, 28 million are women. Compared to men, women also experience more frequent and severe migraines and don't respond as well to drug treatments. Findings from a new study conducted in rats reveal that females may be more susceptible to migraines and less responsive to treatment because of the way fluctuations in the hormone [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.